American Journal of Psychiatry

Article	Citations
Broadening the Parameters of Clinical High Risk for Psychosis	485
2024 Annual Meeting: Presidential Address	206
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	142
Evaluating Associations Between Cannabis and Heroin Use	139
Treating Pathologies of the Will	133
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	129
Mental Health Disparities Research: An Introduction to New Directions	119
Highlights From the Residents’ Journal: December 2021	112
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	111
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	110
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	97
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	97
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	96
Depression, Inflammation, and Postpartum Psychosis	94
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	94
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	92
Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	88
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	87
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	87
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	85
On the Genetic and Environmental Relationship Between Suicide Attempt and Death by Suicide	85
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	84
Intentional Drug Overdose Deaths in the United States	82
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	80
New Insights Into Psychotic Disorders	76

Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	72
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	71
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	71
Early Adversity and Development: Parsing Heterogeneity and Identifying Pathways of Risk and Resilience	69
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	68
2024 Annual Meeting: CEO and Medical Director’s Address	67
Highlights From the Residents’ Journal: September 2021	66
Correcting Overestimations in Self-Harm Visit Data	62
APA Council Reports	61
Highlights From the Residents’ Journal: September 2024	60
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	59
Correction to Poirot et al.	58
Suicide and the Menstrual Cycle	56
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	56
The First Large GWAS Meta-Analysis for Postpartum Depression	56
Corrigendum to Morley et al.	56
Coordinate Network Mapping: An Emerging Approach for Morphometric Meta-Analysis	55
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	53
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	52
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	52
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	51
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	51
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	51
Familial Risk of Postpartum Psychosis	51
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	50
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	49
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	46
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	45
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	44
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	44
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	43
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	43
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	43
From Crisis to Action: Psychiatry’s Ethical Imperative to Defend Transgender People’s Rights, Dignity, and Access to Care	42
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	42
The Neglected Role of Psychotherapy for Treatment-Resistant Depression	42
Comment on “Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank”	42
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities	41
Risk of Incident Psychosis and Mania With Prescription Amphetamines	40
Alcohol and the Etiology of Depression	40
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	40
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	38
Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome	38
2021 Articles of Import and Impact	38
Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial	38
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder	35
Suicide in Black Females	35
Cigarette Smoking and Heavy Alcohol Drinking: The Challenges and Opportunities for Combination Treatments	35
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	34
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	34

Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia	34
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	34
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	34
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	33
Psilocybin: From Psychiatric Pariah to Perceived Panacea	33
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	33
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	32
Neuromodulation Strategies for the Treatment of Depression	32
Correction to Baum et al.	30
Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	30
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	30
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	30
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	30
Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	30
Toward Precision Noninvasive Brain Stimulation	30
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	30
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	29
Innovative Directions to Advance Mental Health Disparities Research	29
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	29
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	28
Beneath the Phenotypic Surface: Pleiotropy Shapes the Co-Occurrence of Alcohol Use Disorder and Psychopathology	28
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	28
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	28
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	28
When Will There Be Good News?	28
Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD	27
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	27
Interindividual Differences in Cortical Thickness and Their Genomic Underpinnings in Autism Spectrum Disorder	27
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	27
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	27
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	26
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	26
The Amygdala and Depression: A Sober Reconsideration	26
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	26
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	25
2024 Articles of Import and Impact	25
Auditory Steady-State Responses Probe GABA-Related Oscillatory Cortical Circuits and Their Relation to Neurodevelopmental Mental Disorders	25
Ketamine After Two Antidepressants?	25
Correction	25
Highlights From the Residents’ Journal: December 2024	24
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	24
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	23
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	23
Progress and Challenges in GxE Research on Depression	23
Recommendations for the Usage of Ketamine and Esketamine	23
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg	22
Functional Connectivity Mapping for rTMS Target Selection in Depression	22
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	22
Cannabis Use and the Endocannabinoid System: A Clinical Perspective	22
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	22
Time Course of Relapse Following Acute Treatment for Anorexia Nervosa	22
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	22
Technology and Mental Health: State of the Art for Assessment and Treatment	22
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial	21
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	21
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	21
Antidepressants and Bipolar Disorder: The Plot Thickens	20
Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence	20
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	20
Reports to the Membership	20
Perinatal Mental Health: Advances and Opportunities	20
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	19
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	19
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	19
Anticholinergic Medication Burden–Associated Cognitive Impairment in Schizophrenia	19
Behavior as Physiology: How Dynamical-Systems Theory Could Advance Psychiatry	19
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	19
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?	19
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	19
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon	18
Vaccines as Immunotherapies for Substance Use Disorders	18
Focusing on Substance Use Disorders, Opioids, and Craving	18
Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features	18
Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	18
Putting Genetics to Work in the Psychiatric Clinic	18
Neglect of Adverse Effects in Treatment Guidelines for Depression	18
Psychotropic Drug–Related Weight Gain and Its Treatment	18
Highlights From the Residents’ Journal: September 2023	18
An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	18
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	17

Effects of County-Level Opioid Dispensing Rates on Individual-Level Patterns of Prescription Opioid and Heroin Consumption: Evidence From National U.S. Data	17
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	17
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	17
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	17
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	17
Increased Inflammation in Depression: A Little in All, or a Lot in a Few?	17
Don’t Throw the Baby Out With the Bathwater: A Need for Nuanced Practice and Additional Research on Telehealth Management of ADHD	16
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	16
Disclosure of Editors’ Financial Relationships	16
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	16
Reports to the Membership	16
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	16
Polygenic Risk Scores and Genetics in Psychiatry	16
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	16
Improved Response Inhibition Through Cognition-Guided EEG Neurofeedback in Men With Methamphetamine Use Disorder	16
Prospective Associations Between Structural Brain Development and Onset of Depressive Disorder During Adolescence and Emerging Adulthood	15
New Insights Into Major Depression and the Treatment of Bipolar Depression	15
Highlights From the Residents’ Journal: June 2025	15
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	15
Intergenerational Effects of the Fast Track Intervention on Next-Generation Child Outcomes: A Preregistered Randomized Clinical Trial	15